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In this study, we found that expression and secretion of galectin-3 (GAL-3) were upregulated by
amyloid-b42 (Ab42) exposure in human umbilical cord blood-derived mesenchymal stem cell
(hUCB-MSC) without cell death. Ab42-exposed rat primary cortical neuronal cells co-treated with
recombinant GAL-3 were protected from neuronal death in a dose-dependent manner. hUCB-MSCs
were cocultured with Ab42-exposed rat primary neuronal cells or the neuroblastoma cell line, SH-
SY5Y in a Transwell chamber. Coculture of hUCB-MSCs reduced cell death of Ab42-exposed neurons
and SH-SY5Y cells. This neuroprotective effect of hUCB-MSCs was reduced signiﬁcantly by GAL-3 siR-
NA. These data suggested that hUCB-MSC-derived GAL-3 is a survival factor against Ab42
neurotoxicity.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Since human umbilical cord blood-derived mesenchymal stem
cells (hUCB-MSC) is capable of differentiating into mesodermal
origin, such as bone, cartilage, and adipose, our institute has con-
ducting a phase III clinical trial for cartilage regeneration (Clinical-
Trials.gov Identiﬁer: NCT01041001) under approval of the Korea
Food and Drug Administration (KFDA). In their allogeneic reac-
tions, hUCB-MSC is known to be stable immunologically, due to
the absence of expression of major histocompatibility complex
(MHC) class II and T-cell co-stimulatory factors [1]. In addition,
hUCB-MSC suppresses allogeneic responses of lymphocytes under
mixed lymphocyte reaction conditions [2]. Therefore, hUCB-MSC
transplantation should be considered safe for use in stem cell
therapy.
Recently, therapeutic effects of hUCB-MSC on brain disease
have been reported. For example, glioma-tropism of hUCB-MSC
was proposed as a vehicle carrying suicide gene for glioma therapy
[3,4]. In addition, hUCB-MSC transplantation improved a Nie-
mann–Pick type C (NP-C) disease mouse model via modulation of
neuroinﬂammation [5]. Collectively, these data suggested that
hUCB-MSC should be regarded as a fascinating source for cell ther-
apy for neurological disorders.chemical Societies. Published by E
anmail.net (J.W. Chang).Alzheimer’s disease (AD) is an incurable neurodegenerative dis-
ease that is characterized by loss of neurons by amyloid-b (Ab)
neurotoxicity [6]. AD progresses by gliosis and neuronal and syn-
aptic loss, causing progressive loss of memory and cognitive func-
tion [7]. Recently, transplantation of rat or mouse neural stem cells
(NSC) [8,9] and mouse bone marrow MSC resulted in improved
cognition in transgenic AD mice [10].
In this study, we found for the ﬁrst time that human UCB-MSC
has a neuroprotective effect in vitro against Ab42 toxicity via secre-
tion of galectin-3. Galectin-3 (GAL-3), known as a neuroprotective
factor, was actively secreted by Ab42 exposure in hUCB-MSC. Our
data demonstrated potential therapeutic effects of hUCB-MSC via
secretion of beneﬁcial factors, including GAL-3.
2. Materials and methods
2.1. Preparation of hUCB-MSC
This study was approved by the Institutional Review Board of
MEDIPOST Co., Ltd. Umbilical cord blood was collected from umbil-
ical veins after neonatal delivery with informed consent of the
pregnant mothers. MSCs were isolated by separation of mononu-
clear cells (MNC) using a Ficoll-Hypaque solution (d = 1.077 g/
cm3; Sigma). Following transfer to a-minimum essential medium
(a-MEM; Gibco) supplemented with fetal bovine serum (FBS; Gib-
co), MNCs were seeded in culture ﬂasks at 5  105 cells/cm2. Cellslsevier B.V. All rights reserved.
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dle-shaped cells. At 50% conﬂuence, cells were harvested after
treatment with 0.25% (w/v) trypsin–EDTA (Gibco) and were resee-
ded for expansion [11].
2.2. Cell culture and treatment
All procedures for rat primary cortical and hippocampal neuron
culture were conducted in accordance with institutional guidelines
under the approved protocols. Pregnant Sprague–Dawley rats were
purchased from Orientbio (Korea). Brain tissues were dissected
from embryonic day 14 rat cortex and hippocampus tissues, and
cells were mechanically dissociated in Ca2+/Mg2+-free Hank’s bal-
anced salt solution. Initial cell seeding density was 3  103/cm2.
Cells were allowed to proliferate in the presence of 20 ng/ml of ba-
sic ﬁbroblast growth factor (bFGF) in serum-free Neurobasal media
(Invitrogen). Cell proliferation was maintained in Neurobasal med-
ia containing bFGF for 4 days in order to reach 80% conﬂuence prior
to induction of differentiation by withdrawal of bFGF. The differen-
tiation was induced in Neurobasal media without B27 supplement
for 10 days. B27 supplement was not used in all culture proce-
dures. During differentiation period, Neurobasal media was chan-
ged in every 2 days. After 10 days differentiation, cells were
stained by anti-MAP2, GFAP, CD11b and nestin antibodies to eval-
uate percentage of neuron, astrocyte, microglia and neural progen-
itor cell. Percentage of each cell type was shown in Supplementary
Fig. 1. Ab42 treated neuronal cells were cocultured with hUCB-MSC
or treated with GAL-3 protein (R&D Biosystems) for 24 h. Rat pri-
mary neuronal cells or SH-SY5Y cells were treated with 10 lM of
Ab42 (Sigma), and human recombinant GAL-3 for 24 h. Ab42 was
solubilized in phosphate-buffered saline (PBS) and the stock was
stored at 4 C for 3 days and divided to aliquots at 80 C. GAL-3
was dissolved in PBS containing 0.1% bovine serum albumin
(BSA) and aliquoted at 80 C. As a control, MRC5 human ﬁbro-
blast cells (ATCC) were cultured under culture conditions that were
identical to those of hUCB-MSC. hUCB-MSC (8  104 cells/cm2)
were cocultured in an upper chamber (pore size: 1 lm) with
Ab42-exposed rat primary neuronal cells or SH-SY5Y cells in a
Transwell chamber (Falcon).
2.3. Real-time PCR
For total RNA isolation, cells were lysed using TRIzol Reagent
(Invitrogen). mRNA was reversely transcribed to cDNA. Ampliﬁca-
tion was performed with the Lightcycler real-time PCR
(Roche Diagnostics) system using Lightcycler TaqMan Master mix
(Roche), sequence-speciﬁc probes (Roche), and the following spe-
ciﬁc primers: human Gal-3 forward 50-gagcctaccctgccactg-30,
reverse 50-aggcaaaggcaggttataagg-30; RNA polymerase II forward
50-cctccaggtggttcagagg-30, reverse 50-agttccaacaatggctaccg-30 was
used for the control gene. Data analysis of relative gene expression
was performed with the DDCt technique using the reference gene
as a calibrator.
2.4. Immunostaining and LIVE/DEAD staining for quantitative analysis
Cultured cells were ﬁxed in 4% paraformaldehyde/0.15% picric
acid in phosphate-buffered saline and were incubated with each
anti-antibody. The following primary antibodies were used: tubu-
lin b III (Sigma), microtubule-associated protein 2 (MAP2)
(Millipore), glial ﬁbrillary acidic protein (GFAP) (Millipore), nestin
(Chemicon) and cleaved caspase-3 (Cell signaling). The image
was analyzed using a ﬂuorescent microscope (Nikon) and a confo-
cal microscope (ZEISS, LSM 510 META). For objective assessment of
cell death, a LIVE/DEAD Viability/Cytotoxicity kit (Invitrogen) was
utilized according to instructions. All quantitation was performedby cell count using i-Solution software (IMT i-Solution INC). Per-
centage of MAP2-positive cell was calculated by the ratio of num-
ber of MAP2-positive cells to DAPI-positive total cell number. Cell
viability (%) was analyzed by a ratio of number of green colored
cells to total number of cell in a LIVE/DEAD staining.
2.5. Western blot analysis
Cell extracts were prepared by ultrasonication (Branson) in buf-
fer containing 9.8 M urea, 4% CHAPS, 130 mM DTT, 40 mM Tris–Cl,
and 0.1% SDS. Secreted proteins of conditioned media were precip-
itated in ice-cold acetone at 20 C for overnight. After centrifuga-
tion, precipitated proteins were solubilized in the same buffer for
cell extracts. Protein amount was measured by the Bradford assay
(Bio-RAD). The protein extract (20 lg) and precipitated protein
from media (15 lg) were loaded on SDS–PAGE for separation of
proteins. Proteins were transferred to a nitrocellulose membrane
(NC) and then incubated with anti-GAL-3 (R&D Biosystem) or
cleaved caspase-3 or caspase-3 (Cell signaling) and b-tubulin (Sig-
ma) antibody. Protein was visualized by Enhanced Chemilumines-
cence (ECL) (GE Healthcare). The analysis of caspase-3 activation in
Western blot was analyzed by QuantityOne software (Bio-RAD).
2.6. siRNA treatment
For knock down of GAL-3 expression, control siRNA or siRNA for
GAL-3 (Bioneer, Korea) was mixed with Lipofectamine™2000
(Invitrogen). hUCB-MSC were treated with this mixture for 6 h in
antibiotic-free media containing 2% FBS. After 6 h, siRNA treated
cells were kept for 48 h in serum-free media for evaluation of re-
duced secretion level of GAL-3. In coculture with Ab42-exposed
SH-SY5Y cells, hUCB-MSC treated with each siRNA for 24 h were
trypsinized, and detached 8  104 cells/cm2 cells were added to
the upper chamber of the Transwell for additional 24 h.
2.7. ELISA
For measurement of GAL-3 in conditioned media, media were
ﬁltered by syringe ﬁlter (0.2 lm, Millipore). Secreted GAL-3 was
measured using the DuoSet ELISA Development System (R&D Sys-
tems) following a recommended manual. Results were analyzed at
450 nm using a microplate reader, VERSAmax (Molecular Devices).3. Results
3.1. Expression and secretion of GAL-3 were upregulated by Ab42 in
hUCB-MSC
Since RT-PCR analysis revealed that the level of GAL-3 mRNA
was increased by Ab42 exposure in hUCB-MSC (data not shown),
we performed real-time PCR for further analysis. Compared to
control cells, the transcriptional level of GAL-3 was upregulated
by an average of 6.2-fold in the Ab42-exposed hUCB-MSC group
(Fig. 1A). For analysis of the protein level of GAL-3 by Ab42
exposure, cell lysates and conditioned media of hUCB-MSC were
collected in a time-dependent manner and analyzed by Western
blot analysis. Although GAL-3 does not contain a signal peptide
for secretion, secretion of GAL-3 by non-classical pathways has
been reported [12]. Intracellular and extracellular GAL-3 was
upregulated by Ab42 treatment in a time-dependent manner
(Fig. 1B). b-Tubulin of Western blot and stained membrane by
Ponceau S were loading control for lysate and media in Western
blot analysis, respectively. In order to measure concentration of
secreted GAL-3 by Ab42 treatment, the same sample of Fig. 1B
was analyzed by ELISA. Concentration of secreted GAL-3 by
Fig. 1. Ab42 induced upregulation of GAL-3 expression and secretion in hUCB-MSC. (A) hUCB-MSC was treated with Ab42 for 24 h in serum-free media. Total RNA was
isolated from each cell and GAL-3 expression was analyzed by real-time RT-PCR. (B) Cell lysates and concentrated conditioned media were separated by SDS–PAGE and then
immunoblotted with anti-GAL-3 antibody. Tubulin was analyzed for evaluation of loading amount in cell lysate. The Ponceau S staining of NC membrane was used for loading
control of media. (C) Concentrated each medium was analyzed by ELISA according to a recommended instruction. (D) For analysis of the effect of Ab42 on hUCB-MSC and rat
primary neuronal cells, cells exposed to Ab42 for 24 h underwent LIVE/DEAD staining. Red and green colors indicate nuclei of dead cells and live cells, respectively. (E) Cell
viability (%) was analyzed by the ratio of the number of green colored cells to the total number of cells. Value represents mean ± SE of three independent experiments.
*P < 0.05 vs MSC without Ab42. **P < 0.05 vs neuron without Ab42.
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Although Ab42 induced cell death in rat primary cortical neuro-
nal cell, it had no effect on viability of hUCB-MSC in LIVE/DEAD
staining (Fig. 1D and E). A green/red color indicated live cell/nu-clei of dead cells (Fig. 1D). After LIVE/DEAD staining, percentage
of cell viability was quantitated by cell counting (Fig. 1E). These
data suggested that Ab42 induced upregulation and secretion of
GAL-3 in hUCB-MSC without cell death.
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primary neuronal cells
Since GAL-3 has been proposed as a neuronal survival factor
[13], we tested whether recombinant GAL-3 treatment rescues
Ab42 neurotoxicity or not. Ab42-exposed rat primary cortical neu-Fig. 2. Treatment of recombinant GAL-3 protected Ab42 neurotoxicity of rat primary n
Materials and Methods. Primary cortical neurons exposed to Ab42 were co-treated with
with anti-MAP2 antibody was performed for calculation of the percentage of surviving
positive cells was shown in (B). Value represents mean ± SE of three independent exper
from duplicate cells of (A) and analyzed by Western blot analysis with anti-caspase-3. (
indicated the ratio of cleaved form to full-length capspase-3. Value represents mean ±
were preincubated with GAL-3 recombinant protein (500 pg/ml) for 20 min. This mixtu
DEAD staining and the percentage of dead cell was analyzed by cell counting. **P < 0.05
protein. Ct indicates cortical neurons.ronal cells underwent simultaneous dose-dependent treatment
with recombinant GAL-3. For analysis of surviving neurons under
Ab42 neurotoxicity, neurons were selected by immunostaining
with anti-MAP2 antibody (Fig. 2A). MAP2-positive neurons were
counted for survival as rated by treatment with GAL-3 protein
(Fig. 2B). Recombinant GAL-3 signiﬁcantly protected cell death ineurons. Differentiated neuronal cells were obtained by the procedure described in
recombinant GAL-3 in a dose-dependent manner. (A) After 24 h, immunostaining
neurons. The image was captured by confocal microscope. Percentage of MAP2-
iments. *P < 0.05 vs Ab42-exposed cortical neurons. (C) Cell extracts were collected
D) The result of Western blot was quantitated by densitometric analysis. The graph
SE of three-independent experiments. (E) Sucrose (100 mM) and lactose (100 mM)
re was treated to SH-SY-5Y cells with Ab42 for 24 h. each cell was stained by LIVE/
vs Ab42-exposed cortical neuron. ***P < 0.05 vs Ab42-exposed SH-SY5Y with GAL-3
Fig. 3. Coculture of hUCB-MSC protected Ab42-exposed rat primary neurons and SH-5Y5Y cells. For evaluation of the neuroprotective effect of hUCB-MSC, hUCB-MSC was
cocultured simultaneously with Ab42-exposed rat primary neuronal cells (A–C) or SH-5Y5Y cells, human neuroblastoma cells (D–F) for 24 h, respectively. As a control, non-
related human ﬁbroblasts were also cocultured. (A) After coculture, rat primary hippocampal neuronal cells were stained by anti-tubulin bIII antibody. (B) Percentage of tubulin
bIII positive neuronwas calculated. (C) Protection of cleavage of caspase-3 in rat primary cortical neurons by hUCB-MSCwas analyzed by immunostaining. In themerged image,
the red color indicates cleaved caspase-3 and the blue color shows DAPI staining. (D) In coculture, Ab42-exposed SH-SY5Y cells were cocultured with hUCB-MSC for 24 h and
analyzed by LIVE/DEAD staining. (E) Percentage of dead cells was analyzed under each condition. (F) Cell lysates from (D) were analyzed by Western blot analysis with anti-
caspase-3 antibody. (G) The result of Western blot was quantitated by densitometric analysis. The graph indicated that a ratio of cleaved form to full-length capspase-3. Value
represents mean ± SE of three-independent experiments. ***P < 0.05 vs Ab42-exposed SH-SY5Y cells. Hippo and Ct indicated hippocampal and cortical neurons, respectively.
Value of (B) and (E) represent mean ± SE of each three-independent experiments. *P < 0.05 vs Ab42-exposed hippocampal neurons. **P < 0.05 vs Ab42-exposed SH-SY5Y.
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ner. In this experiment, the counting of DAPI-positive cells showed
that GAL-3 treatment did not affect cell proliferation (Supplemen-
tary Fig. 2). In addition, cleavage of caspase-3 was monitored byFig. 4. Knock down of GAL-3 by siRNA reduced neuroprotection effect of hUCB-MSC. (A
siRNA for 48 h in the presence of Ab42, and secreted GAL-3 was measured by ELISA. (
cocultured simultaneously with Ab42-exposed SH-SY5Y cells for another 24 h in a Transw
(C) Duplicated cell lysates were analyzed by anti-caspase-3 antibody. The precursor c
analysis. (D) The graph indicated a ratio of cleaved form to full-length capspase-3. Value r
CON siRNA SH-SY5Y. (E) Duplicated cells were immunostained by anti-cleaved caspase-3
represent mean ± SE of each three-independent experiments *P < 0.05 vs CON siRNA anWestern blot analysis and a ratio of cleaved form to full-length
caspase-3 was analyzed by densitometric analysis. Treatment with
GAL-3 reduced activation of caspase-3 in a dose-dependent man-
ner by Ab42 exposure (Fig. 2C and D). In order to know a role of su-) To set up conditions for knock down of GAL-3, hUCB-MSC was treated with each
B) As a control, hUCB-MSC treated with CON-siRNA or GAL-3 siRNA for 24 h were
ell chamber. After LIVE/DEAD staining, percentage of surviving cells was calculated.
aspase-3 (32 kDa) and the cleaved form (17 kDa) were detected by Western blot
epresent mean ± SE of three-independent experiments. ***P < 0.05 vs Ab42-exposed
antibody. Red (caspase-3) and blue (DAPI) colors were merged. Value of (A) and (B)
d **P < 0.05 vs Ab42-exposed SH-SY5Y.
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GAL-3 (500 pg/ml) was preincubated with sucrose and lactose
(each 100 mM). This mixture was treated to Ab42-exposed neuro-
blastoma cell line, SH-SY5Y cells. If carbohydrate-recognition do-
main is involved in neuroprotection, lactose and sucrose could be
competitive [13]. To analyze percentage of dead cells, cells were
stained by LIVE/DEAD staining. In percentage of dead cell, neuro-
protection of GAL-3 increased signiﬁcantly by sugars treatment
(Fig. 2E). These data suggested that carbohydrate-recognition do-
main may participate in negative regulation for neuroprotection
on GAL-3. Collectively, these data suggested that GAL-3 could pro-
tect Ab42-mediated neurotoxicity.
3.3. Coculture of hUCB-MSC protected Ab42 induced cell death of SH-
SY5Y and rat primary neurons
Since we observed a survival effect of GAL-3 against Ab42
neurotoxicity and GAL-3 was actively secreted from hUCB-MSC
by Ab42 exposure, hUCB-MSCs, or, as a control, non-related human
lung ﬁbroblast cells, MRC5 were cocultured simultaneously with
Ab42-exposed rat primary hippocampal neuronal cells for 24 h
cells in a Transwell chamber. Since pore size of the upper chamber
is 1 lm, there is no cell contact. However, secreted proteins can
pass through pores between hUCB-MSC and primary neuronal
cells. Following Ab42 exposure, we examined cell death rate by
immunostaining with anti-tubulin bIII (Fig. 3A). Tubulin bIII posi-
tive cells were counted for analysis of survival neurons (Fig. 3B).
Ab42-exposed rat primary neurons showed typical cell death
patterns, including alteration of neurite; however, these cells
sustained viability dramatically by coculture of hUCB-MSC. How-
ever, MRC5 were not protective against neuronal cell death in a
Transwell chamber. In addition, this event was also conﬁrmed with
rat primary cortical neuronal cells by immunostaining of anti-cas-
pase-3 (cleaved form). As expected, cleaved caspase-3 (red color)
by Ab42 neurotoxicity was reduced signiﬁcantly by coculturing
with hUCB-MSC, but not with MRC5 (Fig. 3C). For further study
involving knock down of GAL-3 by siRNA, we conducted the same
experiment with SH-SY5Y human neuroblastoma cells because rat
primary neuronal cells were mixed neuronal and glial cells. We
performed coculture of hUCB-MSC with Ab42-exposed SH-SY5Y
cells (Fig. 3D). From LIVE/DEAD staining, we observed similar data
on rat primary neuronal cells (Fig. 3E). Cleaved caspase-3 was re-
duced dramatically by coculturing of hUCB-MSC in Western blot
analysis (Fig. 3F and G). These data suggested that hUCB-MSC res-
cued Ab42 toxicity in cortical and hippocampal neurons.
3.4. Knock down of GAL-3 abolished the neuroprotective effect of
hUCB-MSC
Since we observed a neuroprotective effect against Ab42-ex-
posed SH-SY5Y cells by hUCB-MSC coculture (Fig. 3) and Ab42 in-
duced GAL-3 expression in hUCB-MSC (Fig. 1), we attempted to
inhibit expression of GAL-3 in hUCB-MSC. We tested inhibition of
GAL-3 by three different siRNAs, and reduced secretion of GAL-3
was conﬁrmed by ELISA. Three siRNAs demonstrated signiﬁcant
and efﬁcient inhibition of GAL-3 secretion in the presence of
Ab42 (Fig. 4A). hUCB-MSC were treated with siRNA1 and the three
mixed siRNAs for 24 h, and were then cocultured simultaneously
for an additional 24 h with Ab42-exposed SH-SY5Y cells, respec-
tively, for determination of the neuroprotective role of GAL-3 in
hUCB-MSC. In LIVE/DEAD staining, control siRNA treated hUCB-
MSC protected Ab42 neurotoxicity; however, this effect was re-
duced signiﬁcantly by GAL-3 siRNA(s) treatment (Fig. 4B). Each
duplicated cell was analyzed by immunostaining and Western blot
analysis with anti-capspase-3 antibody (Fig. 4C and E). Similar re-
sults of LIVE/DEAD staining were conﬁrmed by analysis of caspase-3. A ratio of cleaved form to full-length capspase-3 was analyzed
by densitometric analysis according to Figs. 2 and 3 (Fig. 4D).
Above data were conﬁrmed again by the staining of cleaved cas-
pase-3 (Fig. 4E). These data suggested that the neuroprotective ef-
fect of hUCB-MSC was mediated via GAL-3.4. Discussion
In the early stage of stem cell therapy, regeneration medicine
was the primary interest. In the point of view of regeneration med-
icine for AD therapy using stem cells, overcoming AD seems impos-
sible due to widespread loss of neurons in the brain. Recently,
Block et al. reported on a paracrine effect of stem cells; BM-MSC se-
creted STC-1 for anti-apoptosis in UV-irradiated skin ﬁbroblasts
[14]. In addition, hBM-MSC improved cardiac function after myo-
cardial infarction via secreted TSG-6 [15]. These data emphasized
that stem cells are robust sources, not only for regeneration, but
also for secretion of survival factors for damaged cells.
In our data, we proved that hUCB-MSC secrete beneﬁcial fac-
tors, including GAL-3, under pathological conditions such as
Ab42 exposure. Although Ab42 induced potential neuronal cell
death, Ab42 stimulated secretion of GAL-3 as a neuroprotective
factor in hUCB-MSC without cell death (Fig. 1). GAL-3 is a multi-
functional protein involved in adhesion, growth, and intracellular
and nuclear transcription [16,17]. Although GAL-3 dose not contain
signal peptides for secretion, it can be detected outside the cell
[12,18]. In particular, functions of the extracellular form of GAL-3
have been reported in cell activation, TCR signaling, cell adhesion,
migration, and IL-5 secretion, depending on cell type [19,20].
Secretion of GAL-3 seems to be enhanced by certain stimuli, be-
cause a low level of GAL-3 was detected by Western blot analysis
in conditioned media of naïve hUCB-MSC (Fig. 1B). However, after
Ab42 exposure, GAL-3 was strongly detected in conditioned media
of hUCB-MSC. Similar data, such as calcium ionophore induced
secretion of GAL-3, has been reported [21]. According to ﬁndings
from a previous report, when GAL-3 was immobilized as a substra-
tum, GAL-3 promoted notable neural cell adhesion and neurite
outgrowth [13]. Furthermore, these activities were inhibited by
polyclonal antibody and additive sugar including sucrose and lac-
tose for GAL-3. This paper suggested that GAL-3 is a survival factor
for neurons via cell adhesion and neurite outgrowth. In our study,
recombinant GAL-3 treatment protected Ab42 neurotoxicity in a
dose-dependent manner (Fig. 2). Since GAL-3 contains domain
for carbohydrate-binding, we tested the involvement of this do-
main (Fig. 2E). The rate of cell death by Ab42 was more declined
by preincubation of GAL-3 with sugar than that of GAL-3 protein
alone. These data indicated that neuroprotection of GAL-3 could
be regulated by the binding of intracellular sugar containing pro-
tein. Therefore, we should further study using truncated GAL-3 to
characterize a critical domain for neuroprotection on GAL-3 and
try to ﬁnd intracellular GAL-3 binding partner containing carbohy-
drate for negative regulation. Since hUCB-MSC secreted GAL-3 un-
der Ab42, we expected that coculture of hUCB-MSC may rescue
Ab42 neurotoxicity. Our expectation was conﬁrmed in rat primary
hippocampal and cortical neurons using a coculture system (Fig. 3).
Moreover, inhibition of GAL-3 secretion by siRNA reduced the neu-
roprotective effect of hUCB-MSCwith neuronal cells (Fig. 4). In pre-
vious report [13], GAL-3 served as a substratum for cell adhesion
and neurite outgrowth. Since adhesion cell requires attachment
to survive because interaction between receptor and substratum
activates intracellular signaling [22]. Under pathological condi-
tions of Ab, secreted GAL-3 from hUCB-MSC should stimulate neu-
ron survival through its counter receptors and support for neural
cell adhesion and outgrowth for cell maintenance against Ab42
exposure. Stem cell transplantation has been attempted in
3608 J.-Y. Kim et al. / FEBS Letters 584 (2010) 3601–3608AD-transgenic mice for evaluation of its possibility for use in stem
cell therapy. Lee et al. reported that mouse BM-MSC transplanta-
tion reduced Ab deposit and improved memory deﬁcit in an AD
mice model [10]. Although several new drugs targeting reduction
of Ab level have failed in clinical trials for improvement of declined
cognition [23], stem cell transplantation showed a therapeutic ef-
fect on memory deﬁcit via Ab removal. This result may be due to
simultaneous action of diverse secretory factors from stem cells,
including GAL-3, under pathological conditions. When stem cells
were transplanted in AD mice, stem cell-derived factors partici-
pated not only in Ab removal but also in anti-apoptosis, inﬂamma-
tion, and neurogenesis. Therefore, we can observe combined
therapeutic effects in a stem cell transplanted animal study. Cur-
rently, we are investigating functions of 14 secreted proteins from
hUCB-MSC under Alzheimer’s pathological conditions in order to
understand the molecular mechanism of the therapeutic effect by
hUCB-MSC transplantation (unpublished data). Among 14 proteins,
GAL-3 is one of the secreted proteins with active involvement in
anti-apoptosis against Ab42 neurotoxicity. Although neuroprotec-
tive effect of GAL-3 alone was almost same with that of hUCB-
MSC coculture (Fig. 2), cell therapy with hUCB-MSC has several
advantages. The ﬁrst, GAL-3 can protect Ab42 neurotoxicity how-
ever it cannot recover neuron loss in AD. Transplanted hUCB-
MSC differentiated into neuron and then improved neurological
deﬁcit in disease model [24–26]. These data suggested that trans-
planted hUCB-MSC could participate in functional regeneration of
damaged area. The second, hUCB-MSC has ability to modulate
inﬂammation. Inﬂammation is associated with many neurodegen-
erative diseases including Alzheimer’s disease [27]. Many results
suggested that inhibition of inﬂammation will be able to reverse
or slow progression of AD. Human MSC including BM-MSC and
UCB-MSC can perform anti-inﬂammatory action on inﬂammatory
diseases [28–30].
Collectively, we found that hUCB-MSC protected Ab42 neuro-
toxicity via secretion of GAL-3. Based on these data, we suggest
the potential of hUCB-MSC as a new source of stem cell therapy
for treatment of Alzheimer’s disease.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.febslet.2010.07.028.
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